Donafenib after ablation for recurrent liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer that has come back for the first or second time.
- The recurrence is within the last year.
- The tumor or tumors are small enough to meet the Milan criteria (a single tumor ≤5 cm, or up to 3 tumors each ≤3 cm).
- Your liver is working well (Child-Pugh A or B) and you are able to care for yourself (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs for people with advanced liver cancer whose disease got worse after their first treatment. The goal is to see if this new mix can help control the cancer better and give patients more time.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This study tests a combined treatment for liver cancer that cannot be removed with surgery. It combines a targeted therapy pill (donafenib) with a procedure that delivers chemotherapy directly to the tumor (E-TACE). The goal is to see if this combination helps control the cancer and is safe for patients.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed therapy given before surgery to shrink tumors in people with early-stage liver cancer that can be removed. The goal is to make surgery more successful and improve outcomes.
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.